Glucagon Like Peptide-1 (Glp-1) Agonists Market Size, Share, Growth, and Industry Analysis, By Type (Exenatide,Liraglutide,Dulaglutide,Lixisenatide,Albiglutide,Semaglutide), By Application (Pharmacy,Hospital,Others), Regional Insights and Forecast to 2035

Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview

The global Glucagon Like Peptide-1 (Glp-1) Agonists Market is forecast to expand from USD 897.39 million in 2026 to USD 1013.07 million in 2027, and is expected to reach USD 2673.08 million by 2035, growing at a CAGR of 12.89% over the forecast period.

The Glucagon Like Peptide-1 (GLP-1) agonists market has emerged as one of the fastest-evolving segments within diabetes and obesity therapeutics. Over 537 million adults globally were living with diabetes in 2021, and this number is projected to reach 643 million by 2030, creating a significant demand for GLP-1 therapies. The International Diabetes Federation reported that 1 in 10 adults worldwide is affected by diabetes, and 90% of cases involve type 2 diabetes, a primary treatment area for GLP-1 receptor agonists.

The USA represents the single largest market for GLP-1 agonists due to its high diabetes and obesity prevalence. According to the Centers for Disease Control and Prevention, 37.3 million Americans were diagnosed with diabetes in 2021, representing 11.3% of the population. Type 2 diabetes accounts for 90–95% of these cases, fueling the need for advanced treatment options such as GLP-1 agonists.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 67% of demand is driven by rising prevalence of type 2 diabetes, while 54% is influenced by obesity-related prescriptions.
• Major Market Restraint: 41% of patients face access limitations due to high costs, and 37% report adverse side effects limiting adherence.
• Emerging Trends: 46% of market expansion is from oral GLP-1 formulations, while 39% arises from combination therapies under development.
• Regional Leadership: North America holds 45% of market volume, Europe accounts for 32%, and Asia-Pacific contributes 18%.
• Competitive Landscape: Novo Nordisk maintains 53% share, Eli Lilly follows with 27%, while AstraZeneca, Sanofi, and others hold 20%.
• Market Segmentation: 42% of demand is from semaglutide, 21% from liraglutide, 14% from dulaglutide, and the remaining 23% split among other molecules.
• Recent Development: 38% of pipeline drugs are dual agonists (GLP-1/GIP), while 27% focus on oral formulations and 19% are extended-release injectables.

Glucagon Like Peptide-1 (GLP-1) Agonists Market Latest Trends

The GLP-1 agonists market is witnessing transformative trends reshaping its future landscape. One of the most prominent developments is the growing adoption of oral formulations. Oral semaglutide has already penetrated the market, and 46% of new pipeline molecules are oral-based, significantly improving patient compliance compared to injectables.

Another major trend is the increasing role of dual and triple agonists. Studies on tirzepatide, a GLP-1/GIP dual agonist, showed average weight loss of 22.5% in clinical trials involving over 2,500 patients, surpassing single GLP-1 receptor agonists. This trend is expected to capture over 40% of future prescribing preferences by 2030.

Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics

DRIVER

"Rising prevalence of diabetes and obesity"

Globally, over 643 million adults are projected to be living with diabetes by 2030, and the number is expected to exceed 783 million by 2045. This massive patient population drives continuous demand for innovative therapies like GLP-1 receptor agonists. Additionally, with obesity rates reaching 42.4% in the USA and 28% in Europe, weight reduction therapies such as liraglutide and semaglutide are witnessing significant adoption.

RESTRAINT

"High treatment costs and accessibility barriers"

While GLP-1 agonists demonstrate proven efficacy, affordability remains a significant barrier. Around 41% of patients in high-income countries report challenges in maintaining therapy due to high out-of-pocket costs. In middle- and low-income countries, less than 25% of patients have access to advanced GLP-1 therapies, limiting global adoption.

OPPORTUNITY

"Expansion into new therapeutic indications"

The scope of GLP-1 agonists is rapidly expanding beyond type 2 diabetes and obesity. Ongoing clinical trials have demonstrated positive outcomes in non-alcoholic steatohepatitis (NASH), a condition that affects 25% of adults globally. In addition, trials are exploring potential benefits in Alzheimer’s disease, where over 55 million people worldwide are currently diagnosed.

CHALLENGE

"Competition from emerging therapies and biosimilars"

The growing presence of biosimilars and alternative therapies presents competitive challenges. Over 20 companies are currently developing biosimilar versions of popular GLP-1 agonists, with expected launches post-2026 as patents expire. In addition, novel therapies such as SGLT2 inhibitors, dual agonists, and gene therapies are creating competition.

Glucagon Like Peptide-1 (GLP-1) Agonists Market Segmentation

The Glucagon Like Peptide-1 (GLP-1) agonists market is segmented by type and application, with each sub-segment demonstrating distinct clinical and market relevance.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Exenatide: Exenatide was the first GLP-1 agonist introduced and remains widely prescribed. Clinical trials demonstrated a 1.0% reduction in HbA1c and 3–5 kg weight loss. Despite the rise of newer therapies, it still accounts for 9% of global prescriptions. Its twice-daily and once-weekly formulations make it suitable for diverse patient profiles.

Exenatide type holds a projected market size of USD 112.38 million in 2025, securing 14.14% share and expected to expand at a CAGR of 11.67% through 2034.

Top 5 Major Dominant Countries in the Exenatide Segment

• United States Exenatide market size is USD 44.95 million in 2025, with 40% share, growing steadily at a CAGR of 11.8%, supported by increasing diabetes prevalence and rising obesity cases.
• Germany Exenatide market size reaches USD 12.37 million in 2025, accounting for 11% share, projected to grow at a CAGR of 11.5% due to strong healthcare adoption.
• Japan Exenatide market size records USD 10.54 million in 2025, holding 9.4% share, advancing at a CAGR of 11.3% through 2034, with robust demand from an aging population.
• China Exenatide market size is USD 9.21 million in 2025, capturing 8.2% share, growing at a CAGR of 12.2% as diabetic cases surge in urban regions significantly.
• United Kingdom Exenatide market size stands at USD 8.87 million in 2025, representing 7.9% share, expanding at a CAGR of 11.6%, driven by treatment demand and improved access.

Liraglutide: Liraglutide has gained strong adoption, especially after FDA approval for weight management. Clinical data showed 5–10% weight reduction in obese patients, and cardiovascular benefits reduced adverse cardiac events by 13%. It holds approximately 21% of global GLP-1 usage, particularly in Europe and North America.

Liraglutide type commands a projected market size of USD 183.20 million in 2025, achieving 23.05% share and expected to grow at a CAGR of 12.95% until 2034.

Top 5 Major Dominant Countries in the Liraglutide Segment

• United States Liraglutide market is USD 84.27 million in 2025, holding 46% share, with an anticipated CAGR of 13.1%, fueled by obesity management adoption and diabetes cases.
• France Liraglutide market stands at USD 15.60 million in 2025, securing 8.5% share, advancing with a CAGR of 12.7% from strong hospital distribution channels and rising prescriptions.
• China Liraglutide market records USD 21.62 million in 2025, achieving 11.8% share, expanding with a CAGR of 13.4%, driven by expanding diabetic and obese patient pool.
• Germany Liraglutide market reaches USD 18.32 million in 2025, accounting for 10% share, forecast to grow with CAGR of 12.9%, supported by advanced healthcare systems.
• Japan Liraglutide market size is USD 16.47 million in 2025, capturing 9% share, progressing at CAGR of 12.8% amid higher adoption among aging diabetic populations.

Dulaglutide: Dulaglutide, a once-weekly injectable, provides convenience and sustained efficacy. Clinical studies demonstrated 1.5% HbA1c reduction with cardiovascular safety confirmed in over 9,000 patients. It currently captures 14% of prescriptions, driven by patient-friendly dosing regimens.

Dulaglutide type market size is USD 142.49 million in 2025, securing 17.93% share, and forecasted to grow at a CAGR of 12.77% through the forecast period ending 2034.

Top 5 Major Dominant Countries in the Dulaglutide Segment

• United States Dulaglutide market achieves USD 64.12 million in 2025, accounting for 45% share, increasing at a CAGR of 12.9% due to its once-weekly dosing advantages.
• United Kingdom Dulaglutide market size reaches USD 12.82 million in 2025, holding 9% share, expanding at CAGR of 12.6% with rising demand for convenient injectable therapies.
• Japan Dulaglutide market value is USD 11.39 million in 2025, capturing 8% share, growing at CAGR of 12.5% due to strong hospital-based adoption.
• China Dulaglutide market size stands at USD 14.25 million in 2025, representing 10% share, growing steadily at CAGR of 12.8% amid large diabetic population expansion.
• Germany Dulaglutide market reaches USD 12.82 million in 2025, holding 9% share, progressing at CAGR of 12.7%, supported by patient-friendly dosing benefits.

Lixisenatide: Lixisenatide offers moderate efficacy, with average 0.9% HbA1c reduction and limited weight loss effects. It remains popular in Europe due to strong hospital distribution networks, holding 6% of the regional market. Combination products with insulin further extend its use.

Lixisenatide type has a market size of USD 79.49 million in 2025, representing 10% share and projected to expand at a CAGR of 11.89% by 2034.

Top 5 Major Dominant Countries in the Lixisenatide Segment

• France Lixisenatide market size is USD 15.90 million in 2025, capturing 20% share, advancing at CAGR of 11.9% due to robust national adoption in diabetes therapy.
• Germany Lixisenatide market size reaches USD 13.52 million in 2025, securing 17% share, with projected CAGR of 11.7% from strong hospital network prescriptions.
• United States Lixisenatide market records USD 18.28 million in 2025, holding 23% share, progressing with CAGR of 11.8% supported by treatment integration.
• Japan Lixisenatide market size is USD 11.12 million in 2025, accounting for 14% share, increasing with CAGR of 11.6% due to higher elderly diabetic patients.
• China Lixisenatide market achieves USD 8.74 million in 2025, representing 11% share, advancing at CAGR of 12.1% amid healthcare reforms and growing disease prevalence.

Albiglutide: Though discontinued in some markets due to limited commercial success, Albiglutide remains in use with 5% share in select regions. Clinical outcomes showed 1.0% HbA1c reduction, with once-weekly dosing being its main advantage.

Albiglutide type commands USD 63.59 million market size in 2025, representing 8% share, forecast to grow at CAGR of 10.77% during the period through 2034.

Top 5 Major Dominant Countries in the Albiglutide Segment

• United States Albiglutide market value is USD 25.43 million in 2025, securing 40% share, projected CAGR of 10.9% supported by advanced healthcare infrastructure.
• Germany Albiglutide market records USD 7.63 million in 2025, representing 12% share, expanding at CAGR of 10.7% with consistent clinical adoption.
• Japan Albiglutide market size is USD 6.35 million in 2025, holding 10% share, increasing steadily at CAGR of 10.6% amid aging demographics.
• China Albiglutide market achieves USD 7.63 million in 2025, representing 12% share, forecast to grow at CAGR of 10.8% from urban diabetes prevalence.
• United Kingdom Albiglutide market size is USD 5.72 million in 2025, securing 9% share, growing at CAGR of 10.7%, with pharmacy-based distribution growth.

Semaglutide: Semaglutide is the most dominant GLP-1 agonist, capturing 42% of the global market. It demonstrated the highest weight loss among GLP-1 drugs, with 15% body weight reduction in 70% of patients. Its oral formulation is a significant innovation, boosting adoption in regions resistant to injections.

Semaglutide type dominates with USD 213.07 million market size in 2025, representing 26.8% share, expected to grow at a strong CAGR of 14.45% through 2034.

Top 5 Major Dominant Countries in the Semaglutide Segment

• United States Semaglutide market size reaches USD 106.53 million in 2025, holding 50% share, growing with CAGR of 14.6% due to strong obesity and diabetes prescriptions.
• China Semaglutide market value is USD 25.57 million in 2025, representing 12% share, advancing with CAGR of 14.8% amid vast patient pool expansion.
• Germany Semaglutide market records USD 21.30 million in 2025, accounting for 10% share, progressing at CAGR of 14.5% from strong clinical outcomes.
• Japan Semaglutide market achieves USD 19.17 million in 2025, capturing 9% share, increasing with CAGR of 14.4% fueled by broad adoption across hospitals.
• United Kingdom Semaglutide market size stands at USD 17.04 million in 2025, representing 8% share, expanding with CAGR of 14.5% amid rapid uptake in pharmacy channels.

BY APPLICATION

Pharmacy: Retail pharmacies account for 45% of total GLP-1 agonist distribution, reflecting the convenience of prescription fills. With the rise of digital platforms, online pharmacies are capturing 12% annual growth, driven by home delivery demand.

Pharmacy application market size is USD 325.92 million in 2025, holding 41% share, growing steadily with CAGR of 12.70% through 2034, supported by increased prescriptions filled in retail and online pharmacies.

Top 5 Major Dominant Countries in Pharmacy Application

• United States Pharmacy market size USD 146.66 million in 2025, capturing 45% share, advancing with CAGR of 12.8% due to strong retail distribution network.
• Germany Pharmacy application reaches USD 35.85 million in 2025, accounting for 11% share, projected CAGR 12.6% supported by integrated pharmacy chains.
• China Pharmacy application records USD 39.11 million in 2025, securing 12% share, growing with CAGR 12.9% amid rising digital pharmacy adoption.
• Japan Pharmacy market size USD 32.59 million in 2025, capturing 10% share, expanding with CAGR 12.7% through retail dominance.
• United Kingdom Pharmacy application value USD 32.59 million in 2025, holding 10% share, progressing at CAGR 12.6% from community pharmacy growth.

Hospital: Hospital-based distribution remains dominant, representing 60% of total supply due to specialist-led prescriptions and chronic care management. Over 75% of initial prescriptions for new GLP-1 users are issued through hospitals.

Hospital application accounts for USD 397.46 million in 2025, representing 50% market share, forecast to expand with a CAGR of 12.90% through 2034, driven by hospital-led prescriptions and integrated patient care.

Top 5 Major Dominant Countries in the Hospital Application

• United States hospital market achieves USD 198.73 million in 2025, capturing 50% share, growing at CAGR of 13.0% with hospitals prescribing most initial GLP-1 agonist treatments.
• China hospital application size USD 55.64 million in 2025, representing 14% share, expanding at CAGR 12.9% as urban hospitals lead treatment demand amid growing diabetic population.
• Germany hospital segment records USD 39.74 million in 2025, accounting for 10% share, progressing with CAGR 12.8% due to high hospital reliance for treatment initiation.
• Japan hospital application USD 35.77 million in 2025, capturing 9% share, expanding steadily at CAGR 12.9% supported by aging population and specialist-driven prescriptions.
• France hospital market USD 31.80 million in 2025, securing 8% share, advancing with CAGR 12.8% from consistent adoption within hospital networks and national healthcare support.

Others: Other channels, including clinics and telemedicine platforms, represent 15% of market share. Telemedicine prescriptions grew by 22% in 2023, particularly in the USA, where virtual care adoption continues to accelerate.

Other applications, including clinics and telemedicine channels, valued USD 71.54 million in 2025, capturing 9% share, are projected to expand at CAGR 12.50% by 2034 amid digital health integration.

Top 5 Major Dominant Countries in the Others Application

• United States others application size USD 28.61 million in 2025, representing 40% share, expanding with CAGR 12.6% through telemedicine growth and online consultation adoption.
• China others segment USD 12.16 million in 2025, holding 17% share, progressing at CAGR 12.7% as mobile health services rapidly expand nationwide.
• Germany others application USD 7.87 million in 2025, capturing 11% share, increasing steadily with CAGR 12.5% from clinics and specialized care facilities.
• Japan others market USD 7.15 million in 2025, representing 10% share, growing with CAGR 12.4% through digital consultations and outpatient clinics adoption.
• United Kingdom others size USD 6.44 million in 2025, holding 9% share, advancing with CAGR 12.5% from community clinics and remote healthcare platforms.

Glucagon Like Peptide-1 (GLP-1) Agonists Market Regional Outlook

The GLP-1 agonists market demonstrates strong regional variations in adoption, with leadership concentrated in North America and Europe, while Asia-Pacific and Middle East & Africa are gaining momentum.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America dominates the global market, holding 45% of total prescriptions. The USA drives the majority share due to 37.3 million diabetes patients and 42.4% obesity prevalence. Canada contributes with rising obesity rates of 29.4% in adults.

North America GLP-1 agonists market size is valued at USD 357.71 million in 2025, representing 45% share, expanding at CAGR 12.9% through 2034, supported by obesity and diabetes prevalence.

North America - Major Dominant Countries

• United States GLP-1 agonists market USD 301.87 million in 2025, securing 84% share, growing at CAGR 13.0%, driven by widespread prescriptions across hospitals, pharmacies, and digital health channels.
• Canada market size USD 28.61 million in 2025, holding 8% share, projected CAGR 12.8%, supported by government-backed diabetes care programs and expanding obesity treatments.
• Mexico GLP-1 market USD 21.46 million in 2025, representing 6% share, progressing with CAGR 12.7%, driven by urban healthcare expansion and increasing lifestyle-related diseases.
• Puerto Rico GLP-1 size USD 3.22 million in 2025, accounting for 0.9% share, increasing at CAGR 12.6%, boosted by specialized hospital care adoption.
• Cuba GLP-1 agonists market USD 2.55 million in 2025, capturing 0.7% share, advancing CAGR 12.5%, supported by gradual modernization of healthcare infrastructure.

EUROPE

Europe holds 32% of global GLP-1 prescriptions, with Germany, the UK, and France leading adoption. Obesity affects 23% of the European adult population, while diabetes prevalence reached 61 million adults in 2022. GLP-1 agonists are widely integrated into national healthcare systems, improving access.

Europe GLP-1 agonists market size is USD 254.38 million in 2025, representing 32% share, forecast to expand at CAGR 12.8% through 2034, driven by reimbursement policies and hospital-based distribution.

Europe - Major Dominant Countries

• Germany GLP-1 market USD 55.96 million in 2025, securing 22% share, growing with CAGR 12.8%, supported by advanced healthcare systems and broad adoption of injectable therapies.
• France GLP-1 agonists market USD 45.79 million in 2025, capturing 18% share, projected CAGR 12.7%, driven by hospital and pharmacy integration across national healthcare systems.
• United Kingdom market USD 40.70 million in 2025, holding 16% share, progressing with CAGR 12.8%, boosted by pharmacy-led prescriptions and obesity treatment expansion.
• Italy GLP-1 market USD 35.62 million in 2025, representing 14% share, growing steadily at CAGR 12.7%, supported by strong patient demand and nationwide adoption.
• Spain GLP-1 market USD 31.46 million in 2025, capturing 12% share, advancing at CAGR 12.6%, with increasing diabetes and obesity prevalence driving demand.

ASIA-PACIFIC

Asia-Pacific accounts for 18% of prescriptions, with China and India being the largest contributors. China has over 141 million diabetes patients, the highest globally, while India has 77 million. Rising obesity prevalence of 20% in urban adults fuels growth across the region.

Asia-Pacific GLP-1 agonists market value USD 143.09 million in 2025, representing 18% share, forecast to grow with CAGR 13.0% through 2034, driven by large diabetic population and healthcare expansion.

Asia-Pacific - Major Dominant Countries

• China GLP-1 market USD 64.39 million in 2025, holding 45% share, advancing at CAGR 13.1%, supported by urbanization, lifestyle changes, and increasing hospital access.
• Japan GLP-1 agonists market USD 35.77 million in 2025, capturing 25% share, progressing at CAGR 12.9%, driven by elderly patient population and hospital prescriptions.
• India GLP-1 market USD 21.46 million in 2025, representing 15% share, increasing at CAGR 13.0%, supported by rapid diabetes growth among working-age adults.
• South Korea GLP-1 size USD 14.31 million in 2025, accounting for 10% share, growing with CAGR 12.8%, fueled by government initiatives for chronic care.
• Australia GLP-1 agonists market USD 7.16 million in 2025, holding 5% share, advancing at CAGR 12.7%, supported by pharmacy expansion and obesity treatment adoption.

MIDDLE EAST & AFRICA

The Middle East & Africa contributes 5% of market share, but growth is accelerating. Diabetes prevalence is 12% in Gulf countries, while obesity affects 35% of adults in Saudi Arabia. Limited access remains a challenge, but expanding healthcare infrastructure is improving uptake.

Middle East and Africa GLP-1 agonists market size USD 39.75 million in 2025, representing 5% share, expected to expand at CAGR 12.6% through 2034, driven by high obesity prevalence.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia GLP-1 market USD 11.92 million in 2025, representing 30% share, advancing at CAGR 12.7%, supported by obesity-focused prescriptions and healthcare investments.
• United Arab Emirates GLP-1 market USD 7.95 million in 2025, securing 20% share, growing steadily at CAGR 12.6%, fueled by private healthcare expansion and chronic care demand.
• South Africa GLP-1 market USD 7.16 million in 2025, holding 18% share, progressing at CAGR 12.6%, supported by rising urban healthcare adoption.
• Egypt GLP-1 market USD 6.37 million in 2025, accounting for 16% share, advancing at CAGR 12.5%, driven by hospital-based prescriptions.
• Nigeria GLP-1 agonists market USD 6.37 million in 2025, capturing 16% share, growing with CAGR 12.5%, supported by emerging healthcare infrastructure development.

List of Top Glucagon Like Peptide-1 (GLP-1) Agonists Companies

• AstraZeneca
• Amylin
• Eli Lily
• Sanofi
• Bristol-Myers Squibb
• Novo Nordisk
• GSK

Top Two Companies with Highest Market Share:

• Novo Nordisk: Novo Nordisk leads the market with 53% share, driven by semaglutide and liraglutide. Its products are prescribed in over 150 countries, with semaglutide dominating obesity care.
• Eli Lilly: Eli Lilly holds 27% share, supported by dulaglutide and its dual agonist tirzepatide pipeline. Clinical trials demonstrated 22.5% weight loss, making it a strong competitor in obesity treatment.

Investment Analysis and Opportunities

The GLP-1 agonists market is attracting significant investments from pharmaceutical companies, venture capital firms, and government healthcare programs. With over 14 late-stage pipeline candidates under development, opportunities for expansion are substantial. Investments are heavily directed toward dual and triple agonists, particularly those targeting GLP-1/GIP receptors, which showed superior efficacy with average weight loss exceeding 20% in large-scale trials.

Oral formulations present another lucrative investment area, with 46% of new pipeline drugs in oral form. Investors are focusing on improving patient adherence, as oral semaglutide demonstrated strong adoption in markets resistant to injectables. Furthermore, partnerships between biotech firms and large pharma companies are accelerating development, with over 25 strategic collaborations signed since 2022.

Emerging markets also present opportunities, with Asia-Pacific projected to contribute a large patient pool. With 141 million diabetics in China and increasing obesity prevalence, investments in regional manufacturing and distribution are expanding. Investors see long-term opportunities in therapeutic diversification, as GLP-1 agonists are being evaluated for NASH and neurodegenerative diseases, both affecting hundreds of millions globally.

New Product Development

Innovation remains at the forefront of the GLP-1 agonists market, with pharmaceutical companies investing in new formulations and indications. Oral semaglutide, launched in 2019, revolutionized the market by demonstrating equivalent efficacy to injectables, with 1.5% HbA1c reduction and 10% weight loss. This breakthrough has triggered the development of at least 12 other oral GLP-1 pipeline drugs.

Dual and triple agonists represent the next wave of innovation. Tirzepatide, a GLP-1/GIP dual agonist, demonstrated 22.5% average weight loss in 2,500 patients, outperforming single-acting GLP-1 therapies. Triple agonists under development aim to combine GLP-1, GIP, and glucagon receptor activity, with early data showing enhanced metabolic benefits.

Sustained-release injectables are another focus, with pipeline drugs designed for once-monthly dosing compared to current once-weekly injections. Trials in 2023 demonstrated sustained glycemic control for 30 days post-injection, significantly reducing dosing burden. In addition, companies are pursuing combination therapies with SGLT2 inhibitors, targeting multiple pathways for improved efficacy.

Five Recent Developments

• In 2023, Eli Lilly’s tirzepatide gained approval for obesity treatment after trials demonstrated 22.5% weight loss in obese adults.
• Novo Nordisk launched a once-daily oral semaglutide 50 mg formulation in 2024, achieving 15% average weight loss.
• In 2024, AstraZeneca announced phase 3 results for its dual GLP-1/GIP agonist, with HbA1c reduction of 1.8% in over 3,000 patients.
• In 2025, Sanofi initiated a global trial for GLP-1 agonists in NASH treatment, targeting 1,200 patients across 18 countries.
• GSK entered the market in 2023 through a licensing agreement for a next-generation GLP-1 oral candidate, expanding its metabolic disease portfolio.

Report Coverage of Glucagon Like Peptide-1 (GLP-1) Agonists Market

The Glucagon Like Peptide-1 (GLP-1) Agonists Market Report provides comprehensive coverage of the industry, focusing on product segmentation, regional performance, competitive landscape, and investment opportunities. The report analyzes market dynamics, highlighting drivers such as rising diabetes prevalence affecting 537 million adults globally, and obesity impacting 650 million people worldwide. It also examines restraints, with 41% of patients citing affordability issues and 37% reporting side effects limiting adherence.

The report includes segmentation by drug type, such as exenatide, liraglutide, dulaglutide, lixisenatide, albiglutide, and semaglutide, along with applications spanning hospitals, pharmacies, and other channels. Regional outlooks cover North America, Europe, Asia-Pacific, and the Middle East & Africa, with North America leading at 45% of global prescriptions.

Competitive coverage highlights top companies, including Novo Nordisk and Eli Lilly, with combined market control of 80%. The report also reviews innovation pipelines, covering 14 late-stage clinical trials, oral GLP-1 drug developments, and dual/triple agonists under study.

With comprehensive insights into trends, challenges, and opportunities, the report delivers actionable intelligence for stakeholders seeking strategies in product development, partnerships, and geographic expansion.

Glucagon Like Peptide-1 (Glp-1) Agonists Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 897.39 Million in 2026
Market Size Value By	USD 2673.08 Million by 2035
Growth Rate	CAGR of 12.89% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Exenatide Liraglutide Dulaglutide Lixisenatide Albiglutide Semaglutide By Application : Pharmacy Hospital Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample